 |
 |
 |
|
Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide
(B/F/TAF) Versus Dolutegravir (DTG)-Based 3-Drug Regimens in
Adults With HIV Who Have Suboptimal Antiretroviral Adherence
|
|
|
ID week 2023 Oct 12
Kristen Andreatta,1 Paul E. Sax,2 David Wohl,3 Michelle L. D'Antoni,1 Hailin Huang,1 Jason Hindman,1 Christian Callebaut,1 Hal Martin1
1Gilead Sciences, Inc., Foster City, CA, U.S.A.; 2Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, U.S.A.; 3Division of Infectious Diseases, University of North Carolina, Chapel Hill, NC, U.S.A.





|
|
|
 |
 |
|
|